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General Introduction and Scope of the Thesis   
  
Cancer is one of the leading causes of death worldwide and one of the top ten causes 
of death in Qatar. Cancer research worldwide aims to enhance the understanding 
of cancer and develop a more effective treatments, which targets cancer cells only, 
with tolerable side effects than the current chemotherapy and radiotherapy.  
There are several pitfalls in the current cancer treatment that are either linked with 
the given drug or to the patient’s immune system. Regarding the drug, it lacks 
selectively, i.e. it damages the healthy tissues as well as the cancer cells. The lack 
of selectivity can cause severe side effects which in many cases terminate the 
treatment.1 The other pitfall is related to the fact that the drug should be given in 
cycles to the patient. This leads the patient’s immune system to raise antibodies 
against the drug, which could hamper the efficacy and efficiency of the medicine.   
Due to the above weaknesses of these conventional treatments the attention has 
been given to the targeted cancer therapy. In this approach, the drug will be  
 
directed mainly to the cancer tissue limiting its side effects and make it more 
tolerable to the patient.   
In this thesis, we focus on two approaches on targeted cancer therapy, one is known 
as the Antibody Directed Enzyme Prodrug Therapy (ADEPT) and the other one is 
Targeted Tumor Superantigens (TTS).    
  
 
In chapter 2, we covered the literature in relation to the targeted cancer therapy 
including our work as shown in the above chapters. The review chapter focused on 
PEGylation and Albumin fusion as the two strategies to produce long acting drugs.  
In chapter 3, 4 and 5, we successfully provided solutions to many limitations in 
the ADEPT, which will make it more effective and efficient. In chapter 6, we 
successfully managed to identify the part on the superantigen molecule which 
cause severe hypotension. This will lead to the production of novel superantigen 
variants to be used in TTS with less side effect.   
Regarding the ADEPT, it is as a two-step approach in cancer treatment. The first 
step involves the administration of a cancer antibody-enzyme conjugate, which 
targets the tumor. Next, a prodrug is injected which will be activated by the enzyme 
at the site of the tumor, in an effort to circumvent the adverse impact on healthy 
tissues. The enzyme can activate many molecules of prodrug, which will result in a 
large amounts of drug being generated at the tumor vacinety.2,3 The activation of 
the prodrug occurs extra cellular and can penetrate the cancer cell by diffusion 
causing cell death.2   
One of the enzymes that is used in this technique is Carboxypeptidase G2 (CPG2) 
also known as glucarpidase. The enzyme CPG2 is a bacterial enzyme and a folate 
hydrolyzing enzyme.   
On the other hand, the enzyme also can degrade the folate analogue, Methotrexate, 
which is used in chemotherapy treatment of cancer. CPG2, therefore, is not only 
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useful in targeted cancer therapy, but also in drug detoxification in case of a high 
doses.3   
In Chapter 3, we successfully isolated a novel glucarpidase to be used in the 
detoxification of drugs and the ADEPT. We isolated novel glucarpidase producing 
bacteria from soil using folate as the only carbon or nitrogen source. We managed 
to isolate three novel enzyme producing bacterial. Two of the enzyme encoding 
genes, Xenophilus azovorans SN213 and Stenotrophomonas sp SA were cloned 
and molecularly characterized.  
In chapter 4, we focused on the use of DNA shuffling to create enzyme variants 
with a new exerted feature, in our case, variants with higher enzyme activities.4 
DNA shuffling is a practical process to induce directed molecular evolution in vitro 
by mimicking natural recombination. In addition to recombination, the technique 
also introduces point mutations at a controlled rate, which broadens the 
possibilities for evolving improved genes.5   
In chapter 4, we successfully implemented the DNA shuffling techniques to 
produce novel CPG2 variants with higher enzyme activity than the wild type. We 
produced a DNA library using the DNA shuffling techniques and screening over 
four thousand variants on folate containing media plates, the variants were 
isolated depending on the desired phenotype. The best three novel variants with 
higher activity glucarpidase were analyzed and sequenced, to recognize the effector 
mutation, and the kinetics of each variant.  
In Chapter 5, we have managed to implement two techniques to extend the serum 
half-life of CPG2 in the ADEPT technique and the detoxification of MTX. The first 
  
 
approach is through PEGylation by the attachment of polyethylene glycol (PEG). 
PEG is a water-soluble and biocompatible polymer, which is used expensively in 
drug delivery. PEG conjugation increases the circulation half-life without affecting 
its activity.6 PEGylation prolongs the circulation time of the conjugated 
therapeutics by increasing its hydrophilicity, reducing the rate of glomerular 
filtration, and masking the antigenic sites. PEG is a non-biodegradable polymer 
and it is primarily excreted through the renal system, whereas higher molecular 
weight PEG chains get eliminated by fecal excretion.6 Another approach that was 
used in our work, is the fusion of the Human Serum Albumin (HSA) to CPG2, HSA 
is an excellent carrier and is responsible for transporting endogenous and 
exogenous compounds with the feature of providing a long average serum half-life. 
It also tends to accumulate around tumors and inflamed tissue sites, which makes 
the fused albumin aid in targeting the therapeutic site of interest. Both new 
variants produced in this chapter have been tested for their, solubility, stability in 
serum and immunogenicity in comparison to the free CPG2.   
In Chapter 6, we focused on the other targeted therapy technique (TTS) as 
mentioned above. We studied the possible production of a new superantigen for 
tolerable cancer immunotherapy. Superantigens (SAGs) are a class of 
immunostimulatory proteins with the ability to activate large fractions of the T cell 
population. Activation requires simultaneous interaction of the SAG with the V 
beta domain of the T cell receptor (TCR) and with major histocompatibility 
complex (MHC) class II molecules on the surface of the antigen-presenting cell.7   
The SAGs are able to non-specifically activate up to 20% of resting T-cells, whilst 
conventional antigen present results in the activation of only 0.001 - 0.0001% of 
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the T-cell population.8 This makes superantigens an excellent target for cancer 
immunotherapy. The use of these molecules however, has a sever side effect such 
as sever vasodilation and hypotension. The purpose of this part of the work is to 
identify the amino acid sequence(s) which contributing to the sever hypotension 
the aim of which is to produce a novel variant of superantigens to be used in 
tolerable cancer immunotherapy.   
Four super antigens (SEA, SEB, SPEA and TSST-1) were codon optimized and 
overexpressed in E .coli. We synthesized peptides to cover the whole molecule and 
we mapped the region which causes vasodilation and therefore, hypotension.     
 Finally in chapter 7, 8 and 9, we provide in three different languages ( English, 
Dutch and Arabic) a comprehensive summery of the results and conclusion as well 
as perspective for future work to be developed on the new and conventional CPG2 
in cancer therapy.  
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